These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 16809632)
41. Compliance to treatment of latent tuberculosis infection in a region of Israel. Bibi H; Weiler-Ravell D; Shoseyov D; Feigin I; Arbelli Y; Chemtob D Isr Med Assoc J; 2002 Jan; 4(1):13-6. PubMed ID: 11802301 [TBL] [Abstract][Full Text] [Related]
42. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835 [TBL] [Abstract][Full Text] [Related]
43. Isoniazid completion rates for latent tuberculosis infection among college students managed by a community pharmacist. Hess K; Goad J; Wu J; Johnson K J Am Coll Health; 2009; 57(5):553-5. PubMed ID: 19254898 [TBL] [Abstract][Full Text] [Related]
45. Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patients. Vadwai V; Shetty A; Soman R; Rodrigues C Scand J Infect Dis; 2012 Jan; 44(1):48-50. PubMed ID: 21923626 [TBL] [Abstract][Full Text] [Related]
46. [The clinical application of quantiferon TB-2G: its usefulness and limitations]. Sato S; Nagai H Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654 [TBL] [Abstract][Full Text] [Related]
47. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2000 Aug; 49(30):685-7. PubMed ID: 10947056 [TBL] [Abstract][Full Text] [Related]
48. [Latent tuberculosis infection: diagnosis and treatment]. Bendayan D; Raz M; Kramer MR Harefuah; 2002 Mar; 141(3):233-6, 316. PubMed ID: 11944212 [TBL] [Abstract][Full Text] [Related]
49. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Anger HA; Proops D; Harris TG; Li J; Kreiswirth BN; Shashkina E; Ahuja SD Clin Infect Dis; 2012 May; 54(9):1287-95. PubMed ID: 22412056 [TBL] [Abstract][Full Text] [Related]
50. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199 [TBL] [Abstract][Full Text] [Related]
51. [Accessibility and compliance of Ethiopian immigrants to latent tuberculosis infection treatment]. Bishara H; Ore L; Bshara H; Vinitsky O; Armaly N; Weiler-Ravell D Harefuah; 2014 Jan; 153(1):8-11, 66. PubMed ID: 24605398 [TBL] [Abstract][Full Text] [Related]
52. Trend and treatment status of latent tuberculosis infection patients in Japan - Analysis of Japan TB Surveillance data. Kawatsu L; Uchimura K; Ohkado A PLoS One; 2017; 12(11):e0186588. PubMed ID: 29091917 [TBL] [Abstract][Full Text] [Related]
53. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. Tuberculosis Research Centre, Indian Council of Medical Research (ICMR), Chennai, India Int J Tuberc Lung Dis; 2011 Jun; 15(6):782-8. PubMed ID: 21575299 [TBL] [Abstract][Full Text] [Related]
54. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Gupta A; Nayak U; Ram M; Bhosale R; Patil S; Basavraj A; Kakrani A; Philip S; Desai D; Sastry J; Bollinger RC; Clin Infect Dis; 2007 Jul; 45(2):241-9. PubMed ID: 17578786 [TBL] [Abstract][Full Text] [Related]
55. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397 [TBL] [Abstract][Full Text] [Related]
56. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823 [TBL] [Abstract][Full Text] [Related]
57. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248 [TBL] [Abstract][Full Text] [Related]
58. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. Rubinowicz A; Bartlett G; MacGibbon B; Greenaway C; Ronald L; Munoz M; Menzies D Int J Tuberc Lung Dis; 2014 Dec; 18(12):1449-54. PubMed ID: 25517810 [TBL] [Abstract][Full Text] [Related]
59. Factors associated with treatment for latent tuberculosis in persons living with HIV/AIDS. Aquino DS; Moura LC; Maruza M; Silva AP; Ximenes RA; Lacerda HR; Miranda Filho Dde B; Albuquerque Mde F Cad Saude Publica; 2015 Dec; 31(12):2505-13. PubMed ID: 26872227 [TBL] [Abstract][Full Text] [Related]
60. The management of tuberculosis: epidemiology, resistance and monitoring. Bang D Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]